公开(公告)号：US20200270214A1

公开(公告)日：2020-08-27

申请号：US16634567

申请日：2019-07-26

申请人： Emory University ,  Mercer University ,  Howard University ,  Union University

发明人： Osman Güner ,  Bernard Lassegue ,  Kathy Griendling ,  Qian Xu ,  David Brown ,  J. Phillip Bowen ,  Amol Kulkarni ,  E. Blake Watkins

IPC分类号： C07D239/26 ,  C07D213/50 ,  C07D213/65 ,  C07D215/14 ,  C07D307/54

摘要： This disclosure relates to compounds and methods of treating or preventing a Nox related disease or condition comprising administering to a subject in need thereof a Nox inhibitor or pharmaceutical compositions comprising a Nox inhibitor disclosed herein, derivatives, or compounds disclosed herein optionally substituted with one or more substitutes including optional salt and prodrug forms. In certain embodiments, this disclosure relates to sulfonylurea compounds and uses reported herein.

公开(公告)号：US20200262940A1

公开(公告)日：2020-08-20

申请号：US16061313

申请日：2016-12-09

申请人： Emory University

发明人： Xuezheng Song ,  Richard Cummings ,  David Fletcher Smith

IPC分类号： C08B37/00

摘要： This disclosure relates to methods of producing glycans from samples containing glycoconjugates using a salt of a hypohalous acid. Methods for producing N-glycans, O-glycans and lipid linked-glycans are provided. Compositions with novel O-glycans or lipid linked-glycans are provided. Methods of producing glycosaminoglycans from samples, particularly animal tissue samples containing proteoglycans, are provided.

公开(公告)号：US20200237556A1

公开(公告)日：2020-07-30

申请号：US16826443

申请日：2020-03-23

申请人： Emory University ,  Georgia Tech Research Corporation

发明人： Mark Prausnitz ,  Henry F. Edelhauser ,  Samirkumar Rajnikant Patel

IPC分类号： A61F9/00 ,  A61M37/00

摘要： Methods and devices are provided for targeted administration of a drug to a patient's eye. In one embodiment, the method includes inserting a hollow microneedle into the sclera of the eye at an insertion site and infusing a fluid drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused fluid drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. The fluid drug formulation may flow circumferentially toward the retinochoroidal tissue, macula, and optic nerve in the posterior segment of the eye.

公开(公告)号：US20200231615A1

公开(公告)日：2020-07-23

申请号：US16822571

申请日：2020-03-18

申请人： Emory University

发明人： Jeffrey Klenc ,  Malgorzata Lipowska ,  Andrew Taylor

IPC分类号： C07F13/00 ,  G01N33/60 ,  G01N33/50 ,  A61K51/04 ,  A61B6/00 ,  C07B59/00

摘要： This disclosure relates to compositions comprising substituted iminodiacetic acid ligands and metal tricarbonyl complexes containing the ligands and derivatives thereof. In certain embodiments, the metal tricarbonyl complexes are used as radioisotope tracers such as renal tracers. In certain embodiments, the metal complexes comprise 99mTc or Re. In certain embodiments, the ligands are substituted with a fluorine, a fluorine-18(F18) radioisotope, or other radionuclide.

公开(公告)号：US20200181242A1

公开(公告)日：2020-06-11

申请号：US16335891

申请日：2017-09-22

申请人： Emory University ,  Rutgers, The State University of New Jersey

发明人： Arash Grakoui ,  Joseph Marcotrigiano

IPC分类号： C07K16/10 ,  C12Q1/686 ,  C12N15/10

摘要： The present disclosure relates to constructs useful in expressing biotinylated monomers and tetramers produced from these monomers. Specifically, the disclosure provides a construct useful in expressing biotinylated antigen monomers, said construct comprising a viral protein of an ectodomain of Hepatitis C Virus (HCV) envelope glycoprotein E2 or Human Immunodeficiency Virus (HIV) gp140. Further disclosed are methods for production and use of these tetramers in identifying and isolating antigen specific B cells and cloning antibodies thereto.

公开(公告)号：US20200179450A1

公开(公告)日：2020-06-11

申请号：US16622071

申请日：2018-06-12

申请人： EMORY UNIVERSITY ,  CHILDREN'S HEALTHCARE OF ATLANTA, INC.

发明人： H. Trent SPENCER ,  Christopher DOERING ,  Sunil RAIKAR ,  Lauren FLEISCHER

IPC分类号： A61K35/17 ,  C07K14/725 ,  C07K16/28 ,  C12N15/86 ,  C07K14/715

摘要： This disclosure relates to engineered cells, such as T-cells, comprising targeted chimeric antigen receptors. In certain embodiments, T-cell targeted chimeric antigen receptors (CAR) are expressed at higher levels when endogenous expression of a T-cell antigen is knocked-down or reduced in the T-cells. In certain embodiments, the engineered cells are immunoregulatory cells genetically modified to prevent or reduce T-cell antigen expression, or the immunoregulatory cells contain a nucleic acid that reduces or knocksdown T-cell mRNA expression, under conditions such that reduced expression of the T-cell antigen results in an increased expression of a chimeric antigen receptor compared to similarly situated immunoregulatory cells wherein the expression of the T-cell antigen is not altered or reduced. In certain embodiments, T-cell antigens include, but are not limited to, CD5, CD7 and CD3.

公开(公告)号：US10675321B2

公开(公告)日：2020-06-09

申请号：US16225281

申请日：2018-12-19

申请人： Emory University ,  University of Iowa Research Foundation

发明人： Cassandra L. Quave ,  James Lyles ,  Alexander R. Horswill

IPC分类号： A61K36/00 ,  A61K36/49 ,  A61K45/06 ,  A61L15/44 ,  A61L15/58 ,  A61L15/40 ,  C11D3/382 ,  C11D3/20 ,  A61L15/46 ,  C11D3/48 ,  A61Q19/00 ,  A61K8/9789 ,  A61K8/97 ,  A61K9/00 ,  A61Q19/10

摘要： This disclosure relates to extracts from chestnut plants and compositions comprising compounds contained therein. In certain embodiments, the extracts are derived from the leaves of a Castanea plant. In certain embodiments, the disclosure relates to methods of treating or preventing bacterial infections, acne, and other related uses.

公开(公告)号：US20200147081A1

公开(公告)日：2020-05-14

申请号：US16733060

申请日：2020-01-02

申请人： Emory University

发明人： Daniel Kalman

IPC分类号： A61K31/506 ,  A61P31/06

摘要： This disclosure relates to the use of kinase inhibitor to treat or prevent infectious diseases such as tuberculosis. In certain embodiments, this disclosure relates to treating or preventing an infectious disease comprising administering an effective amount of a kinase inhibitor or other compound disclosed herein to a subject in need thereof. In certain embodiments, the disclosure relates to methods of treating or preventing tuberculosis comprising administering a kinase inhibitor to a subject in need thereof. In certain embodiments, the subject is diagnosed with Mycobacterium tuberculosis (Mtb) that is resistant to multiple antibiotic agents.

公开(公告)号：US10646580B2

公开(公告)日：2020-05-12

申请号：US15801892

申请日：2017-11-02

申请人： Emory University ,  Georgia Tech Research Corporation ,  Georgia State University Research Foundation, Inc.

发明人： Niren Murthy ,  Eric Seth Gilbert ,  Xinghai Ning ,  Mark Goodman ,  Bryan Stubblefield

IPC分类号： A61K51/00 ,  A61K47/61 ,  A61K49/00 ,  A61K51/06 ,  A61K45/06 ,  C08B31/00 ,  C08L3/04 ,  A61K31/496

摘要： This disclosure relates to conjugates for targeting bacteria and related uses. In certain embodiments, the disclosure relates to methods of transferring a molecule of interest into bacteria comprising mixing bacteria with a non-naturally occurring conjugate under conditions such that the conjugate is transported across the bacterial cell wall. Typically, the conjugate comprises an oligosaccharide and a molecule of interest. In certain embodiments, the molecule of interest may be a tracer or an antibiotic.

公开(公告)号：US10598170B2

公开(公告)日：2020-03-24

申请号：US14450479

申请日：2014-08-04

申请人： EMORY UNIVERSITY ,  GEORGIA TECH RESEARCH CORPORATION ,  CHILDREN'S HEALTHCARE OF ATLANTA, INC.

发明人： Matthew L. Paden ,  Ajit P. Yoganathan ,  Lakshmi Prasad Dasi

IPC分类号： F04B43/067 ,  F04B43/02

摘要： The devices and systems are medical fluid treatment therapies. The device and systems are configured and capable of operating based on small volumes of fluids. The devices and systems include a pump configured for small volume of a fluid. The pump may include a first conduit configured for inflow of the fluid; a second conduit configured for outflow of the fluid; a fluid chamber configured to move the fluid through the pump; a diaphragm configured to force the fluid through the fluid chamber by indirectly exerting force on the fluid chamber; and a connector configured to removably attach the pump to a motor.